Provenge (sipuleucel-T)

Line(s) of Business: HMO; PPO; QUEST Integration
Akamai Advantage

Original Effective Date: 10/01/2015

Current Effective Date: 09/01/2017

POLICY
A. INDICATIONS
The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication
Provenge is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

Compendial Use
Therapy for castration-recurrent metastatic disease for asymptomatic or minimally symptomatic patients with performance status 0-1 and life expectancy greater than 6 months

B. REQUIRED DOCUMENTATION
The following information is necessary to initiate the prior authorization review:
- Current oncology notes and clinical chart notes that include the history of previous treatments (including previous hormone therapy), and any pertinent pathology reports and/or imaging studies (e.g., demonstrating metastatic disease).

C. PRESCRIBER RESTRICTION
The medication must be prescribed by, or in consultation with, an oncologist.

D. EXCLUSIONS
- Members who have received Provenge previously
- Members requesting greater than 3 doses
- Members with hepatic metastases

E. CRITERIA FOR APPROVAL
Prostate Cancer
Authorization of 6 months may be granted for members prescribed Provenge for asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer who do not have hepatic metastases.
F. **DOsing AND ADMINISTRATION**
Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

G. **PROGRAM EXCEPTION – AKAMAI ADVANTAGE**
For Akamai Advantage members, the following apply:
- National Coverage Determination (NCD): Autologous Cellular Immunotherapy Treatment (110.22).
- Compendial Use: Biochemical relapse of nonmetastatic androgen-dependent (castration-naïve) prostate cancer

H. **ADMINISTRATIVE GUIDELINES**

I. **IMPORTANT REMINDER**
The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii’s Patients’ Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA’s determination as to medical necessity in a given case, the physician may request that CVS/caremark reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

J. **REFERENCES**
<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/2015</td>
<td>Original effective date</td>
</tr>
<tr>
<td>05/2016</td>
<td>Annual review</td>
</tr>
<tr>
<td>03/01/2017</td>
<td>Revision effective date</td>
</tr>
<tr>
<td>04/2017</td>
<td>Annual review</td>
</tr>
<tr>
<td>09/01/2017</td>
<td>Revision effective date</td>
</tr>
</tbody>
</table>